AVANT BRANDS INC(TSX:AVNT) stock Fundamental Analysis

Fundamental Rating

Taking everything into account, AVNT scores 3 out of 10 in our fundamental rating. AVNT was compared to 34 industry peers in the Pharmaceuticals industry. AVNT may be in some trouble as it scores bad on both profitability and health. AVNT is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

AVNT had negative earnings in the past year.

In the past year AVNT had a positive cash flow from operations.

AVNT had negative earnings in each of the past 5 years.

In multiple years AVNT reported negative operating cash flow during the last 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -37.92%, AVNT is doing worse than 67.65% of the companies in the same industry.

Looking at the Return On Equity, with a value of -68.65%, AVNT is in line with its industry, outperforming 41.18% of the companies in the same industry.

AVNT has a Return On Invested Capital of 7.27%. This is amongst the best in the industry. AVNT outperforms 88.24% of its industry peers.

		Industry Rank	Sector Rank
ROA	-37.92%
ROE	-68.65%
ROIC	7.27%

ROA(3y)-18.44%

ROA(5y)-20.49%

ROE(3y)-32.03%

ROE(5y)-31.07%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Operating Margin, with a value of 12.55%, AVNT is in the better half of the industry, outperforming 79.41% of the companies in the same industry.

AVNT has a Gross Margin of 45.14%. This is comparable to the rest of the industry: AVNT outperforms 55.88% of its industry peers.

In the last couple of years the Gross Margin of AVNT has remained more or less at the same level.

		Industry Rank	Sector Rank
OM	12.55%
PM (TTM)	N/A
GM	45.14%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.97%

GM growth 5Y-0.04%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), AVNT is destroying value.

AVNT has more shares outstanding than it did 1 year ago.

AVNT has less shares outstanding than it did 5 years ago.

The debt/assets ratio for AVNT is higher compared to a year ago.

2.2 Solvency

AVNT has an Altman-Z score of -0.77. This is a bad value and indicates that AVNT is not financially healthy and even has some risk of bankruptcy.

AVNT has a Altman-Z score (-0.77) which is in line with its industry peers.

The Debt to FCF ratio of AVNT is 44.36, which is on the high side as it means it would take AVNT, 44.36 years of fcf income to pay off all of its debts.

With a Debt to FCF ratio value of 44.36, AVNT perfoms like the industry average, outperforming 58.82% of the companies in the same industry.

AVNT has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.

Looking at the Debt to Equity ratio, with a value of 0.35, AVNT is in line with its industry, outperforming 52.94% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.35
Debt/FCF	44.36
Altman-Z	-0.77

ROIC/WACC0.96

WACC7.57%

2.3 Liquidity

AVNT has a Current Ratio of 1.75. This is a normal value and indicates that AVNT is financially healthy and should not expect problems in meeting its short term obligations.

Looking at the Current ratio, with a value of 1.75, AVNT is in line with its industry, outperforming 50.00% of the companies in the same industry.

AVNT has a Quick Ratio of 1.08. This is a normal value and indicates that AVNT is financially healthy and should not expect problems in meeting its short term obligations.

AVNT has a Quick ratio of 1.08. This is comparable to the rest of the industry: AVNT outperforms 44.12% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.75
Quick Ratio	1.08

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for AVNT have decreased strongly by -280.61% in the last year.

The Revenue has grown by 35.91% in the past year. This is a very strong growth!

The Revenue has been growing by 72.25% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-280.61%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-116.86%

Revenue 1Y (TTM)35.91%

Revenue growth 3Y55.63%

Revenue growth 5Y72.25%

Sales Q2Q%126.79%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

AVNT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AVNT indicates a rather cheap valuation: AVNT is cheaper than 97.06% of the companies listed in the same industry.

Based on the Price/Free Cash Flow ratio, AVNT is valued a bit cheaper than the industry average as 64.71% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	25.63
EV/EBITDA	2.8

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

AVNT does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AVANT BRANDS INC

TSX:AVNT (5/1/2025, 7:00:00 PM)

0.95

+0.02 (+2.15%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)04-14 2025-04-14

Earnings (Next)07-14 2025-07-14

Inst OwnersN/A

Inst Owner ChangeN/A

Ins Owners8.14%

Ins Owner ChangeN/A

Market Cap10.28M

Analysts0

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.29
P/FCF	25.63
P/OCF	20.27
P/B	0.31
P/tB	0.33
EV/EBITDA	2.8

EPS(TTM)-2.32

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)0.04

FCFY3.9%

OCF(TTM)0.05

OCFY4.93%

SpS3.31

BVpS3.04

TBVpS2.9

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-37.92%
ROE	-68.65%
ROCE	10.09%
ROIC	7.27%
ROICexc	7.56%
ROICexgc	7.82%
OM	12.55%
PM (TTM)	N/A
GM	45.14%
FCFM	1.12%

ROA(3y)-18.44%

ROA(5y)-20.49%

ROE(3y)-32.03%

ROE(5y)-31.07%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.97%

GM growth 5Y-0.04%

F-Score5

Asset Turnover0.6

Health

		Industry Rank	Sector Rank
Debt/Equity	0.35
Debt/FCF	44.36
Debt/EBITDA	1.25
Cap/Depr	2.21%
Cap/Sales	0.3%
Interest Coverage	250
Cash Conversion	5.46%
Profit Quality	N/A
Current Ratio	1.75
Quick Ratio	1.08
Altman-Z	-0.77

F-Score5

WACC7.57%

ROIC/WACC0.96

Cap/Depr(3y)30.6%

Cap/Depr(5y)37.88%

Cap/Sales(3y)6.99%

Cap/Sales(5y)7.37%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-280.61%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-116.86%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)35.91%

Revenue growth 3Y55.63%

Revenue growth 5Y72.25%

Sales Q2Q%126.79%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y193.54%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-78.38%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-90.64%

OCF growth 3YN/A

OCF growth 5YN/A

AVANT BRANDS INC (AVNT.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens